Chronic Obstructive Pulmonary Disease | Treatment Algorithms | Claims Data Analysis | US | ALGOIM0035-2021
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) are gaining traction in the chronic obstructive pulmonary disease (COPD) market, threatening the position of both LAMAs and LABAs / inhaled corticosteroids (ICSs). Because of the progressive and irreversible nature of COPD, many patients eventually require more-aggressive treatment and are prescribed a combination of a LABA, a LAMA, and an ICS, providing a market opportunity for the triple-therapy combinations (e.g., Trelegy, Breztri). The launch and uptake of generic versions of blockbuster inhaled drugs (e.g., salmeterol / fluticasone, formoterol / budesonide and albuterol sulfate) increases the affordability of treatment, further changing prescribing patterns.
QUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed COPD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed COPD patients?
- How has Trelegy been integrated into the treatment algorithm, and what is its source of business?
- What percentage of COPD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of COPD patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Mylan, Sunovion, Teva
Key drugs: Advair, AirDuo, albuterol sulfate HFA, Anoro, Bevespi, Breo, Breztri, Brovana, Combivent, Daliresp, Dulera, Incruse, Lonhala, ProAir HFA, Pulmicort, Spiriva, Stiolto, Symbicort, Trelegy, Wixela, Yupelri
SOLUTION ENHANCEMENT
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.
